Does neoadjuvant chemotherapy cancel out the negative survival impact induced by surgical complications after gastrectomy?
ConclusionsNAC may cancel out the negative impact of morbidity on the survival in advanced gastric cancer patients. The prophylactic effects by NAC do not depend on the tumor type or histological response.
CONCLUSION: The modified ypTNM staging system improves the accuracy of OS prediction for patients treated with neoadjuvant chemotherapy followed by gastrectomy with D2 lymphadenectomy. PMID: 31197829 [PubMed - as supplied by publisher]
Publication date: Available online 3 June 2019Source: European Journal of Surgical OncologyAuthor(s): Karol Rawicz-Pruszyński, Jerzy Mielko, Bogumiła Ciseł, Magdalena Skórzewska, Agnieszka Pikuła, Katarzyna Gęca, Tomasz Skoczylas, Tomasz Kubiatowski, Andrzej Kurylcio, Wojciech Piotr PolkowskiAbstractBackgroundSurgical quality assurance is a key element of gastric cancer treatment. The Maruyama Computer Program (MCP) allows to predict lymph node involvement in stations no. 1–16. The aim of the current study was to evaluate the accuracy of the MCP predictions in GC patients treated with neoadjuvant chemothe...
Neoadjuvant chemotherapy for advanced gastric cancer is expected to improve prognoses. However, as there is no method to evaluate neoadjuvant chemotherapeutic efficacy before gastrectomy, some patients at high risk for a poor prognosis undergo gastrectomy. The aim of the present study was to investigate whether endoscopy could assess the efficacy of neoadjuvant chemotherapy.
A 64-YEAR-OLD, 70-kg, 170-cm man presented to the emergency department of the authors ’ institution with acute onset of nausea, vomiting, and diffuse abdominal pain. The patient denied fever, chills, weight loss, heartburn, dysphagia, hematemesis, melena, hematochezia, constipation, abdominal distention, and urinary symptoms. He stated that he had been well until the morning of adm ission. The patient's medical history was notable for gastric cancer that was initially treated with neoadjuvant chemotherapy (consisting of folinic acid, 5-fluorouracil, and oxaliplatin) and radiation therapy (total of 45 Gy in divided do...
ConclusionsThis study defines 30- and 90-day post-operative outcomes after total gastrectomy in a high-volume center. These outcomes data are critical to the improvement of the informed consent process and as benchmarks for future quality improvement initiatives.
Conclusions: The newly developed radiomic signature was a powerful predictor of LN metastasis and the radiomics nomogram could facilitate the preoperative individualized prediction of LN status. Introduction Gastric cancer (GC) is one of the most common malignant tumors and the second leading cause of cancer-related deaths worldwide (1). Accurate evaluation of lymph node metastasis (LNM) status in GC patients is vital for prognosis and treatment decisions (2–4). Some histopathologic factors and biomarkers (e.g., lymphatic invasion, matrix metalloproteinase-2) are found to be able to predict LNM in GC, but mos...
Conclusions: Proximal gastrectomy is feasible and may be safely used in patients with advanced GC after neo-adjuvant chemotherapy with acceptable survival. Posterior esophago-gastrostomy with partial neo-fundoplication reduces the postoperative reflux, while patients with persistent reflux symptoms can be effectively treated with an antireflux therapy.Dig Surg
ConclusionsNAC for type 4 and large type 3 gastric cancer followed by D2 gastrectomy can be safely performed without increasing the morbidity or mortality.
ConclusionsNeoadjuvant chemotherapy including intraperitoneal paclitaxel followed by sequential intravenous paclitaxel and cisplatin with S ‐1 for resectable advanced gastric cancer is feasible and effective.
ConclusionsNeoadjuvant chemotherapy with DCS was feasible and showed a sufficient R0 resection rate. A future study with a sufficient follow-up period should confirm survival outcomes.